Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342765 | 0.84 | PTGDR2 (0.68) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2317111 | 0.84 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2601637 | 0.84 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL20165421 | 0.80 | L3MBTL1 (0.55) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL20165417 | 0.80 | L3MBTL1 (0.55) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10436448 | 0.78 | MAPT (0.51) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10436451 | 0.78 | MAPT (0.51) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL16382639 | 0.78 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL25117781 | 0.76 | MEN1 (0.48) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL9722015 | 0.76 | SMN1; SMN2 (0.50) | MEN1KMT2ASMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066443-B1 | NOVEL METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2017-04-05 | — | — | EP | disclosed |
| US-8536344-B2 | Metathesis catalysts | UMICORE AG & CO. KG (DE) | 2013-09-17 | — | — | US | disclosed |
| US-20130211096-A1 | Novel Metathesis Catalysts | ARLT DIETER (DE) | 2013-08-15 | — | — | US | disclosed |
| US-8288558-B2 | Metathesis catalysts | UMICORE AG & CO. KG (DE) | 2012-10-16 | — | — | US | disclosed |
| CN-101516507-B | Metathesis catalysts | UMICORE AG & CO KG | 2012-05-23 | — | — | CN | disclosed |
| US-20100113795-A1 | NOVEL METATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| CN-101516507-A | Novel metathesis catalysts | UMICORE AG & CO KG (DE) | 2009-08-26 | — | — | CN | disclosed |
| EP-2066443-A1 | NOVEL METATHESIS CATALYSTS | Umicore AG & Co. KG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008034552-A1 | NOVEL METATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113795-A1 | NOVEL METATHESIS CATALYSTS | CYP1B1, CYP51A1, CYP1A1 | MEN1 13/4885KMT2A 2895/4885SMN1; SMN2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.